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ReviewThe Chemical Biology of Apoptosis:
Exploring Protein-Protein Interactions and
the Life and Death of Cells with Small Molecules
The inhibition or promotion of these interactions either
by natural molecules or by unnatural synthetic ones is
of great interest for understanding the mechanism of
biological recognition and translating the information
of gene sequence to the discovery of new therapeutic
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agents. Much progress has been made recently in devel-
oping various strategies to manipulate protein-proteinApoptosis, a fundamental process for both human
interactions with small molecules [7, 8].health and disease, is initiated and regulated by pro-
In apoptosis, protein-protein interactions are the un-tein-protein interactions, notable examples of which
derlying theme in both mitochondria and death receptorare the interactions involving Bcl-2 and IAP protein
pathways (Figure 1). Obviously, life and death are mat-families. This article discusses recent advances in the
ters that cannot be taken lightly. Thus, nature hasuse of chemical approaches in discovering and study-
evolved a sophisticated and tightly controlled networking small molecules targeted to proteins of the Bcl-2
of protein-protein interactions to ensure the accuracyand IAP families. These small molecules and their
and check-and-balance of the cell-death machinery.complexes with receptors provide the tools and model
The activation of caspases, which are central for apopto-systems to probe the basic mechanism of molecule
sis, depends on various protein-protein interactions. Forrecognition underling the life and death of cells and
example, caspase-8 is activated through a cascade ofdevelop novel strategies for therapeutic intervention
sequential oligomerization of death receptors, the adap-of the dysregulated apoptotic process. The review of
tor molecules FADD (Fas-associated protein with deaththese studies highlights the opportunity and challenge
domain), and procaspase-8, whereas caspase-9 is acti-in this emerging area of chemical and chemical biolog-
vated through the association of at least cytochromeical research.
c, Apaf-1, and procaspase-9 to form apoptosome. The
action of these “killer” enzymes before or after activation
Introduction is controlled or safeguarded through protein-protein in-
Apoptosis or programmed cell death is the prevalent teractions involving multiple families of proteins, includ-
mechanism complementary to proliferation that is criti- ing the Bcl-2 (B cell lymphoma-2) and IAP (inhibitor of
cal for the normal development and function of multicel- apoptosis proteins) families, which have recently re-
lular organisms [1]. As approximately 1011–1012 cells are ceived intensive attention.
produced every day in healthy adult humans, this rapid The Bcl-2 family is a large group of apoptosis regula-
proliferation needs to be balanced by apoptosis to main- tors which, through the diverse interactions among
tain a constant cell number. Changing this balance in themselves and with other proteins, control the release
either direction has pathological consequences. Abnor- of apoptogenic factors, such as cytochrome c and Smac
mally high rate of cell death is found in neurodegenera- (second mitochondria-derived activator of caspases) or
tive diseases including Alzheimer’s and Parkinson’s dis- its murine homolog DIABLO (direct IAP binding protein
eases, AIDS and cardiovascular diseases, whereas with low pI), needed for caspase activation [9, 10]. While
retarded cell death contributes to a wide variety of hu- the Bcl-2 family regulates the integrity of mitochondria
man cancers [2]. and normally has little impact on signals from death
There are two major pathways for apoptosis that have receptors, a crosstalk is found in some cells where cas-
been elucidated so far, both of which involve a family pase-8 activated by death receptors cleaves inert Bid
of cysteine proteases with aspartate specificity, called to release tBid, which then triggers the mitochondiral
caspases, as the executioners of apoptosis [3, 4]. The apoptotic pathway (Figure 1). The IAP family is another
mitochondria provide one of the apoptotic pathways family of proteins that reprieve caspases’ execution of
from which cytochrome c is released upon the stimula- apoptosis through physically interacting with caspases
tion by a variety of cell-death triggers [5]. This leads and thereby directly inhibiting their function. In turn, the
to activation of Apaf-1 (apoptosis protease activating function of the IAP family is inhibited by Smac/DIABLO,
factor-1), caspase-9, and caspase-3. Another apoptotic which, upon its release from the mitochondria together
pathway involves the ligation of death receptors such with cytochrome c, binds IAPs and relieves them from
as Fas and activation of caspase-8 and subsequently the complexes with caspases.
caspase-3 [6] (Figure 1). Given the fundamental role of apoptosis in both nor-
Protein-protein interactions are important for a wide mal physiology and a wide variety of human diseases,
variety of physiological as well as pathological pro- there has been an explosion of research in the past
cesses. The significance of protein-protein interactions decade which has made apoptosis one of the central
has never been more apparent than in the post-genome areas in biomedical sciences. There are many recent
era, in which the functional characterization of every reviews in the biological [11–15], clinical [16–19], and
protein encoded by the human genome will require un- structural [20, 21] aspects of apoptosis. This article fo-
derstanding of its molecular interactions with others. cuses on the chemical and chemical biological perspec-
tives of apoptosis in terms of how chemical approaches
are used to explore and control the function of proteins1Correspondence: z-huang@life.uiuc.edu
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Figure 1. Protein-Protein Interactions in Programmed Cell Death
A network of protein-protein interactions along the two apoptotic pathways involving the mitochondria and death receptor.
involved in the regulation of cell death and survival. are described. After that, I will briefly describe some
recent work on peptide ligands of IAPs. In addition toChemists have long favored the dissection and mimicry
of large and complicated biological systems by smaller serving as model systems to probe and understand the
basic mechanism of molecule recognition in pro-and simplified molecular models that are amenable to
chemical synthesis and modification. Such strategies grammed cell death, small molecule inhibitors of Bcl-2
and IAP family proteins have tremendous potential forhave powerful application in the study of apoptosis in
conjunction with genetic, biological, and structural tech- clinical application, as some of them have recently been
shown to be potent anticancer agents.niques. The chemical research of apoptosis often in-
volves the use of small molecules, including synthetic
peptides, natural products, and designed compounds, The Bcl-2 Family: The Molecular “Yin” and “Yang”
in Apoptosisthat mimic or bind specific protein surface sites and
thus modulate their interactions with other proteins. Structure, Function, and Molecular Interactions
The Bcl-2 family proteins are key regulators of the apo-Cell-permeable synthetic peptides and nonpeptidic
molecules targeted to a specific apoptosis-related pro- ptotic pathway involving the mitochondria [9, 10]. Mem-
bers of the Bcl-2 family include both antiapoptotic pro-tein can be used to perturb its function instantaneously
for the dissection and determination of the kinetic time teins, exemplified by Bcl-2, and proapoptotic proteins,
exemplified by Bax. Some features of these proteins arecourse (which is not possible with genetic techniques)
of the complex network of many molecular interactions reminiscent of the ancient Chinese theory of “yin” and
“yang,” which, in an over-simplified interpretation, sym-during apoptotic processes.
In this article, I will discuss the use of chemical ap- bolize two basic opposing elements such as death ver-
sus life, dark versus light, negative versus positive, etc.proaches in discovering and studying small molecules
targeted to the protein-protein interactions involving the (Figure 2). The healthy state relies on the interaction of
yin and yang in a unity of opposites, whereas loss oftwo apoptosis-regulating protein families of Bcl-2 and
IAP. The Bcl-2 family will be the main focus for which this balance results in the abnormal diseased state. In
some sense, prodeath proteins such as Bax and Badrecent advances in the discovery and synthesis of many
different classes of peptide and nonpeptidic inhibitors might be thought to act like yin, whereas the opposite
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Figure 2. The Molecular “Yin” and “Yang“ in
Apoptosis
The interaction and relative ratio of Bcl-2 and
Bax (or their functional homologs), like that
of “yang” and “yin,” is essential for determin-
ing the fate of cells. According to ancient Chi-
nese theory, yin and yang symbolize two ba-
sic opposing elements, such as death versus
life. The healthy state relies on the interaction
of yin and yang in a unity of opposites,
whereas loss of this balance results in the
abnormal diseased state. In many ways, pro-
death proteins, such as Bax, act like yin,
whereas the opposite prolife proteins, such
as Bcl-2, act like yang. Capable of hetero-
dimerization, they neutralize each other’s
function and retain a delicate balance. How-
ever, the excess of either one can tilt the bal-
ance toward cell death or survival.
prolife proteins such as Bcl-2 and Bcl-xL act like yang. tional changes [31] triggered by dephosphorylation [32]
or proteolytic cleavage by caspases (such as the cleav-Capable of heterodimerization, they neutralize each oth-
er’s function and retain a delicate balance. However, age of Bid to generate tBid; Figure 1) [33–35].
the excess of either one can tilt the balance toward cell
death or survival. In terms of sequences, Bcl-2 family The BH3 Domain: Analysis and Mimicry
by Peptidesproteins share at least one of four homologous regions
termed Bcl homology (BH) domains (BH1 to BH4) (Figure BH3 Peptide Binding and Mechanistic Studies
In Vitro or in Cell-free Systems3A). Based on sequence homology, a subclass of pro-
apoptotic proteins termed “BH3-only” can be classified Among the four BH domains of the Bcl-2 family, the BH3
domains in proapoptotic Bcl-2 family members (Figurethat share sequence homology only in the BH3 domain.
While all of proapoptotic members use the BH3 domain 4A) play a key role in cell death by interacting with the
surface pocket of Bcl-2 or Bcl-xL and neutralizing itsto interact with antiapoptotic proteins, BH3-only pro-
teins, including Bad and Bid, appear to act mainly as antiapoptotic activity [36]. The three-dimensional struc-
tures of Bcl-xL and Bcl-2 as determined by X-ray crystal-antagonists of antiapoptotic members such as Bcl-2
and Bcl-xL. In contrast to the opposing biological func- lography and/or NMR spectroscopy reveal a hydropho-
bic surface pocket formed by the BH1-3 domains (Figuretions and wide differences in amino-acid sequences,
experimentally determined structures of Bcl-2 [22], Bcl- 4B) [22, 23]. Residues at the BH1 and BH2 domains are
essential for the antiapoptotic function of Bcl-2 or Bcl-xL [23, 24], Bax [25], and Bid [26, 27] are surprisingly
similar (Figure 3B). xL, as studies have shown that mutations at these sites
abolished their biological function [37]. Death agonists,The mechanism by which Bcl-2 family proteins regu-
late apoptosis has been a subject of intensive research. such as Bax, Bak and Bad, use their BH3 domains to
bind to the surface pocket and promote apoptosis [38–Currently it remains controversial and several models
have been proposed. An attractive mode of action is 40]. How these BH3 domains recognize their antiapo-
ptotic partners and the mechanism by which they triggerthe heterodimerization between antiapoptotic and pro-
apoptotic Bcl-2 family members (Figure 2) [17, 28, 29]. apoptosis have been the subject of much investigation.
Sattler et al. synthesized peptides containing the BH3Some information about the structural basis of these
interactions is provided by the three-dimensional struc- domain of several Bcl-2 family proteins, including Bcl-2,
Bcl-xL, Bax, Bik, and Bak [30]. These synthetic BH3ture of Bcl-xL in complex with a peptide derived from
the BH3 domain of Bak (Figure 4A) [30]. The structure peptides displayed widely different binding affinities to
Bcl-xL, while the peptide derived from Bak BH3 domainreveals a hydrophobic surface pocket on Bcl-xL formed
by the BH1-3 domains bound by the Bak BH3 domain (residues 72–87, see Figure 4A) showed relatively high
binding affinity (KD  0.34 M). The difference in bindingpeptide in helical conformation. Since the BH3 domain
is buried in the structures of proapoptotic proteins Bid affinity of these BH3 peptides derived from different
Bcl-2 family members and Ala-substituted analogs of[26, 27] and Bax [25], this raises the speculation that
conformational changes are necessary for the exposure Bak BH3 peptide was explained by the NMR structure
of Bcl-xL bound by Bak BH3 peptide [30].of the BH3 domain of a proapoptotic protein and its
inhibition of the functional pocket on antiapoptotic part- Compared with other BH3 peptides described above,
the BH3 peptide derived from mouse Bad protein (resi-ners. In the cell environment, proapoptotic Bcl-2 family
members are suggested to undergo such conforma- dues 140–165 of mBad, Figure 4A) showed higher affinity
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Figure 3. The Sequence and Structural Ho-
mology of the Bcl-2 Family
(A) One or more of the four homologous re-
gions termed BH domains (BH1 to BH4)
shared by the Bcl-2 family. A subclass of pro-
apoptotic proteins termed “BH3-only” share
sequence homology only in the BH3 domain.
(B) The structures of Bcl-2 [22], Bcl-xL [23],
Bax [25], and Bid [26, 27] displaying the simi-
larity in their overall structure and folding pat-
tern, despite their opposing biological func-
tions and wide differences in amino-acid
sequences. Note that the C-terminal helix of
Bax, which is a putative transmembrane do-
main and is packed against the surface
pocket on Bax, is not shown in the figure. Also
note that Bid possesses two helical segments
(A and B) in BH4 region, whereas Bcl-2 and
Bcl-xL display a continuous helix combining
these two segments, as denoted by (AB).
for Bcl-xL, with a KD value of 6 nM [41]. The structure 16 amino acids or longer) derived from the BH3 domains
of Bak, Bax, and Bad in blocking the heterodimerizationof Bcl-xL protein complexed with a 25-residue peptide
derived from human Bad BH3 domain (NLWAAQRY of Bcl-xL with death agonists [43, 44]. These BH3 pep-
tides were shown to inhibit Bcl-xL-Bax and Bcl-xL-BadGRELRRMSDEFVDSFKK) was determined by using
NMR spectroscopy [42]. The overall structure is similar interactions in a dose-dependent manner. Consistent
with its high binding affinity to Bcl-xL [41], peptides de-to the complex of Bcl-xL bound by a 16-residue Bak
BH3 peptide. The N and C termini of Bad BH3 peptide rived from Bad BH3 (26 amino acids) were more potent
than other BH3-derived peptides in blocking protein-form additional interactions with Bcl-xL protein. How-
ever, such contacts were suggested to play no major protein interactions involving Bcl-xL.
Cosulich et al. studied the biological activity of syn-role in the increase of receptor binding, based on results
from mutant peptides containing Ala substitutions at N thetic BH3 peptides in triggering apoptosis in a cell-
free system based on extracts of Xenopus eggs [45].and C termini. Rather, it was argued that the high Bcl-xL
binding affinity was contributed by the enhanced helical Peptides of 16 amino acids derived from the BH3 do-
mains of Bak, Bax, or Bid were found to induce apopto-stability of the longer Bad BH3 peptide sequences as
compared with other shorter 16-amino-acid BH3 pep- sis by causing rapid activation of caspases, whereas a
Bak BH3 mutant peptide containing Ala substitution attides. Using an in vitro protein-protein binding assay,
Ottilie, Diaz et al. evaluated the effects of peptides (either Leu-78, which is critical for Bcl-xL binding [30], did not
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introduced into prostate carcinoma PC-3 and DU145
cells by electroporation, these peptides caused apopto-
sis in these cells, which could be blocked by a broad-
spectrum caspase inhibitor zVAD-fmk.
Biological Activity of BH3 Peptides in Intact Cells
In addition to structure and function studies in vitro
and in cell-free systems as described above, synthetic
peptides derived from the Bcl-2 family can be used to
probe and modulate Bcl-2-regulated apoptotic path-
ways in living cells. To do this, one needs to modify
these peptides to make them cell permeable, because
normally peptides have little ability to cross the cell
membrane and arrive at their intracellular targets, such
as Bcl-2 family proteins. Several strategies have been
reported in which synthetic peptides derived from Bcl-2
family proteins are linked with transporter peptides or
nonpeptidic molecules that can deliver functional pep-
tides into the cell.
The internalization domain of the Antennapedia (Ant)
protein, RQIKIWFQNRRMKWKK, has been used in a
number of studies as the transporter to deliver functional
peptides into cells [49–54]. Holinger et al. synthesized
a fusion Ant-BH3 peptide combining the 16-amino-acid
Ant internalization sequence and the Bak BH3 sequence
(residues 71–89, Figure 4A) and found that this fusion
peptide caused the activation of caspases and triggered
apoptosis in intact HeLa cells [55]. While microinjection
of recombinant Bcl-xL into these cells suppressed pro-
grammed cell death induced by Fas, Ant-BH3 peptide
was shown to antagonize the function of Bcl-xL by inhib-
iting its ability to suppress Fas-induced apoptosis. It
was suggested that the cell-killing effect of Ant-BH3
peptide was due to its binding to Bcl-2-related death
antagonists, because a mutant Ant-BH3 peptide con-
Figure 4. The BH3 Domain: Sequences and Complex Structure with
taining a single Ala substitution at Val-78 lost the Bcl-xLBcl-xL
binding activity and was incapable of inducing apopto-(A) The aligned amino-acid sequences of the BH3 domain in repre-
sis. Interestingly, Ant-BH3 appeared to trigger apoptosissentative members of the proapoptotic and BH3-only subfamilies.
in a cytochrome c-independent manner. It did not causeThe amino-acid sequence of the BH3 domain of mouse Bad (mBad)
is shown because it has been used for peptide design. All other the early loss of mitochondrial membrane potential or
BH3 sequences are from human proteins. The numbering of residues cytochrome c release from the mitochondria.
corresponds to that in the native protein. Fatty acids are a class of nonpeptidic molecules that
(B) The three-dimensional structure of Bcl-xL in complex with a can help peptides cross the cell membrane. For exam-peptide derived from the BH3 domain of Bak [30]. This surface
ple, myristic acid and stearic acid have been used forpocket is conserved in other antiapoptotic proteins, such as Bcl-2
the intracellular delivery of peptide inhibitors of protein[22], and proapoptotic proteins, such as Bax [25]. The molecular
recognition of this surface pocket and the BH3 domain determines kinase C [56] and protein-tyrosine phosphatase [57],
the affinity and specificity of protein-protein interactions of the Bcl-2 respectively. Using a smaller fatty acid, the decanoic
family. Thus, peptides or nonpeptidic molecules mimicking the bind- acid, as the cell-permeable moiety (CPM), Wang et al.
ing of the BH3 domain can modulate the function of the Bcl-2 family
synthesized cell-permeable Bcl-2 binding peptides byand be used as novel therapeutic agents.
attaching this CPM to the N terminus of synthetic BH3
peptides [58]. One peptide, termed CPM-1285, that con-
show any effect. Since cytochrome c is involved in the tained the BH3 domain of mouse Bad protein (residues
activation of apoptosis, the activity of synthetic BH3 140–165 of mBad, Figure 4A) was shown to enter human
peptides in affecting cytochrome c release in isolated myeloid leukemia HL-60 cells by confocal microscopy.
rat mitochondria was evaluated. Whereas a 16-amino- The in vitro Bcl-2 binding assay suggested that CPM-
acid peptide derived from Bax BH3 domain was shown 1285 strongly competed with the binding of a fluores-
to lack the activity in inducing cytochrome c release cein-labeled Bak BH3 peptide with an IC50 of 130 nM.
[46], another study observed significant cytochrome c In intact HL-60 cells, CPM-1285 induced the activation
release after treatment with a 20-amino-acid Bax BH3 of caspase-3 and triggered apoptosis characterized by
peptide (residues 55–74) or a 15-amino-acid Bak BH3 DNA fragmentation and cleavage of PARP. The apopto-
peptide (residues 73–87) [47]. Morgan et al. described sis induced by CPM-1285 was dependent on caspase
in a conference report how synthetic peptides derived activation, since the addition of a caspase inhibitor,
from the BH3 domain of Bak or Bax diminished the zVAD-fmk, completely blocked the effect of CPM-1285.
Furthermore, CPM-1285 was shown to slow human my-association of Bcl-2 with Bak in PC-3 cells [48]. When
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eloid leukemia growth in severe combined immunodefi- peptide from its value of the receptor-bound state, they
applied this FP competitive binding assay to analyze thecient (SCID) mice.
In addition to apoptosis induction, the cell-permeable binding affinity of synthetic peptides and nonpeptidic
compounds. The FP-based assay is relatively easy topeptide approach was applied to inhibit apoptosis.
Shimizu et al. showed that the BH4 domain of antiapo- conduct and highly amenable for high-throughput
screening. This assay and its subsequently modifiedptotic Bcl-2 or Bcl-xL was required for inhibiting VDAC
activity and apoptotic release of cytochrome c [59]. Us- protocols using different labeled BH3 peptide probes
have been commonly used for screening compound li-ing the protein transduction domain of HIV TAT protein
that is known to facilitate the delivery of proteins into braries and determining ligand affinity by a number of
groups [22, 42, 65, 67, 68].cells [60–62], they synthesized a fusion TAT-BH4 pep-
tide that combined the HIV TAT domain (RKKRRQRRR) Discovery of Nonpeptidic Inhibitors
of Bcl-2 or Bcl-xLand Bcl-xL BH4 sequence [59]. This TAT-BH4 peptide
prevented apoptosis in HeLa cells, whereas the TAT- In general, it has been a difficult challenge to find small
molecule inhibitors of protein-protein interactions. Thus,only sequence did not show any effect. These results
suggest that peptides mimicking the BH4 domain of even though several assays were available for com-
pound screening, the discovery of small molecule inhibi-antiapoptotic Bcl-2 family proteins, when transferred
into cells, act as inhibitors of apoptosis by suppressing tors of Bcl-2 or Bcl-xL remained elusive until the last two
years, when multiple, different classes of nonpeptidicVDAC activity and subsequently the release of cyto-
chrome c through VDAC. inhibitors were reported. The first inhibitor of Bcl-2 was
reported by Wang et al. in 2000 and was discovered by
using a computer screening strategy [66]. This method
Nonpeptidic Molecules that Inhibit BH3 Domain relies on the high-resolution three-dimensional structure
Binding to Bcl-2 or Bcl-xL of a targeted receptor protein and computer-aided tech-
Methods to Detect Small Molecule Binding niques to search a large number of organic compounds
to Bcl-2 or Bcl-xL for potential ligand molecules. Combining both the ratio-
In addition to synthetic BH3 peptides, nonpeptidic or- nal design by new computational methods and the diver-
ganic molecules that specifically target the BH3 binding sity of existing compound databases, this strategy has
pocket on Bcl-2 or Bcl-xL have been highly sought after become a powerful tool for nonpeptidic ligand discovery
by many groups in both academia and industry. Such [69]. Using this approach, Wang et al. conducted a vir-
nonpeptidic compounds can be used as probes for the tual screening on a computer of a large collection of
research of the molecular recognition of Bcl-2 or Bcl-xL more than 190,000 organic molecules and identified
surface pocket by small molecules and leads for the HA14-1 (Figure 5A) [66]. In vitro binding studies demon-
development of new anticancer agents. Prerequisite to strated the interaction of HA14-1 with the surface pocket
these efforts is the development of accurate and sensi- of Bcl-2 (IC50 9M in competing with the Bcl-2 binding
tive protein-ligand binding assays for screening small of a fluorecein-labeled Bak BH3 peptide). HA14-1 in-
molecules and measuring their affinity with the surface duced apoptosis in HL-60 cells that overexpress Bcl-2.
pocket. Below, a summary is provided for several Bcl-2 In conjunction with the discovery of HA14-1, Yu et al.
or Bcl-xL ligand binding assays which can be divided developed an efficient synthetic method for the prepara-
into two basic types: direct ligand binding detection tion of HA14-1 derivatives, which can facilitate efforts in
and measurement of competition with a known labeled further lead optimization to increase the binding potency
probe for receptor binding. and specificity of HA14-1 analogs for Bcl-2 protein [70].
The earliest method used to detect ligand binding to In 2001, three independent papers describing discov-
the Bcl-2 or Bcl-xL surface pocket was reported by Sat- eries of small molecule inhibitors of Bcl-2 or Bcl-xL were
tler et al., who analyzed the Bcl-xL binding affinity of a published. Using the FP competitive binding assay to
series of synthetic BH3 peptides based on changes in screen a chemical library of 16,320 compounds, Deg-
the fluorescence emission of the Trp residues of Bcl-xL terey et al. identified two classes of small molecule li-
in the presence of increasing concentrations of peptides gands of Bcl-xL, termed BH3I-1 and BH3I-2 because
[30]. Rather than measuring the fluorescence emission they inhibit BH3 peptide binding to Bcl-xL [65] (Figure
of receptor Trp residues, Tzung et al. studied the recep- 5B). These compounds were also shown to inhibit BH3
tor binding of fluorescent compounds such as antimycin peptide binding to Bcl-2. The affinity of these com-
A3 by measuring the increase in fluorescence upon pro- pounds is in the low micromolar range (Ki of 2.4–15.6
tein binding [63]. Yet another method for direct ligand M) as determined by FP and NMR titration assay. The
binding measurement was based on NMR titrations of binding site of the compounds in the surface pocket of
Bcl-xL with inhibitors, as reported by Lugovskoy, Degt- Bcl-xL was estimated by NMR experiments based on
erev et al. [64, 65]. This NMR-based method has the chemical-shift perturbations exhibited by residues on
advantage in providing not only the binding affinity of a Bcl-xL upon compound binding. These compounds were
ligand but also its contact residues on the receptor. shown to induce apoptosis in Jurkat cells overexpress-
Alternative to these methods for direct ligand binding ing Bcl-xL. In a subsequent study, Lugovskoy et al. ana-
measurement, Wang et al. reported a competitive bind- lyzed the structure-activity relationships of these com-
ing assay based on fluorescence polarization (FP) [58, pounds based on NMR and molecular modeling studies.
66]. By labeling a Bak BH3 peptide with 5-carboxyfluo- In addition, they used computer screening to identify
rescein at the peptide’s N terminus and measuring the an analog of BH3I-1 that showed similar binding affinity
to Bcl-xL [64].decrease of fluorescence polarization of the labeled
Review
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chemical shifts as determined by NMR experiments
showed those residues around the BH3 binding pocket
of Bcl-xL to be involved in the binding of compound 6.
The most recent addition to the reported list of non-
peptidic ligands of Bcl-2/Bcl-xL surface pocket was a
series of terphenyl derivatives published by Kutzki et al.
[68]. Previously, this group showed that the terphenyl
scaffold, in a staggered conformation, closely repro-
duces the projection of functionality on the surface of
an helix [74, 75]. Extending this scaffold for the mimicry
of the BH3 helix that binds the Bcl-2/Bcl-xL surface
pocket, they synthesized terphenyl molecules con-
taining alkyl or aryl substituents on the three ortho posi-
tions which were designed to mimic the key hydropho-
bic side chains (i.e., Val-74, Leu-78, Ile-81, and Ile-85)
of Bak BH3 peptide. Such compounds were indeed
found to bind to Bcl-xL as determined by the FP competi-
tive binding assay, with a KD of 114 nM for the most
potent derivative (Figure 5E). Further NMR experiments
and computational docking studies showed that this
compound binds to the same hydrophobic surface
pocket on Bcl-xL as the Bak BH3 peptide.
Clinical Application of Inhibitors of Bcl-2 or Bcl-xL
The Bcl-2 family is implicated in many human diseases.
In particular, cancer is linked to both the original discov-
eries of many genes belonging to this family and much
Figure 5. Nonpeptidic Inhibitors of Bcl-2 and Bcl-xL of subsequent biological research to understand their
The chemical structures of recently discovered nonpeptidic ligands function. The antiapoptotic members of the Bcl-2 family
of Bcl-2 and Bcl-xL, reported by several groups independently, in- are known to contribute to neoplastic cell expansion by
cluding (A) HA14-1 [66], (B) BH3I-1 and BH3I-2 [65], (C) antimycin
preventing normal cell turnover caused by physiologicalA3 [63], (D) compound 6 [67], and (E) a terphenyl derivative [68].
cell-death mechanisms. For example, high levels and
aberrant patterns of Bcl-2 gene expression are found in
a wide variety of human cancers, including 70% ofA natural product, antimycin A (Figure 5C), which is
a known antibiotic and binds cytochrome b [71, 72], was breast cancers,30%–60% of prostate cancers,90%
of colorectal cancers, 60% of gastric cancers, 100%reported by Tzung et al. to have biological activity in
mimicking the death-inducing BH3 domain [63]. Based of small-cell lung carcinomas, 20% of non-small-cell
lung cancers,30% of neuroblastomas,80% of B cellon fluorescence emission spectra, antimycin A was
shown to compete with Bak BH3 peptide binding to the lymphomas, and variable percentages of melanomas,
renal cell, and thyroid cancers, as well as acute andsurface pocket of Bcl-2 and Bcl-xL. Antimycin A inhibited
the pore-forming activity of Bcl-xL in synthetic liposomes chronic lymphocytic and nonlymphocytic leukemias [17,
76]. The expression levels of Bcl-2 proteins also corre-and induced apoptosis in murine hepatocyte cell lines
transfected with Bcl-xL. To address the issue of selectiv- late with relative resistance to a wide spectrum of cur-
rent chemotherapeutic drugs and -irradiation. Sinceity of antimycin A for the Bcl-2 or Bcl-xL targets, an
analog, 2-methoxy-antimycin A3, which was previously Bcl-2 can protect against such a wide variety of drugs
that have very different mechanisms of action, it appearsknown to be inactive as an inhibitor of cytochrome b-c1
[72, 73], was studied and shown to retain binding to that all of these drugs use a common final pathway for
the eventual induction of cell death which is regulatedBcl-2. This suggested the feasibility of using antimycin
A as a template to develop more specific inhibitors of by Bcl-2.
The revealed role of the Bcl-2 family in cancer andBcl-2 or Bcl-xL devoid of general mitochondrial toxicity.
Enyedy et al. used the structure-based computer resistance to cytotoxic therapies has opened new ave-
nues in the development of novel anticancer strategiesscreening approach to search a collection of 206,876
compounds and identified seven compounds that had [77, 78]. An attractive strategy for inducing apoptosis in
cancer cells or overcoming their chemoresistance is toBcl-2 binding with IC50 values by the FP assay ranging
from 1.6 to 14.0 M [67]. Compound 6 was the most inhibit the protective function of Bcl-2 or related anti-
apoptotic proteins such as Bcl-xL that are often over-potent compound and had an IC50 value of 4 M in
reducing the viability of HL-60 cells expressing a high expressed or upregulated in cancer cells. Apoptosis-
inducing activity in cancer cell lines was observed inlevel of Bcl-2 (Figure 5D). It was further shown that com-
pound 6 was active in inducing apoptosis in HL-60 and the above-described small molecule inhibitors of Bcl-2
or Bcl-xL. HA14-1 was shown to induce apoptosis inMDA-231 cells that express Bcl-2 but had much less or
no activity in T47D and MDA453 cells that express low several types of cancer cell lines, including human my-
eloid leukemia (HL-60) [66], breast cancer (MDA-MB-or undetectable levels of Bcl-2. Finally, changes in
Chemistry & Biology
1066
468) [79], and prostate cancer (PC3, LNCaP) (unpub- Future Research in Molecule Recognition
and Drug Design of the Bcl-2 Familylished results from laboratory). The apoptotic effect of
From chemical and structural perspectives, a centralHA14-1 in breast and prostate cancer cells was found
question that needs to be further studied is the mecha-to be dependent on Bcl-2 expression, as the compound
nism by which the BH3 domain recognizes the surfacewas not active in breast and prostate cancer cells that
pocket commonly seen in the Bcl-2 family. The BH3have very low or undetectable levels of Bcl-2. Com-
domain seems to be responsible for the affinity of differ-pound 6 also displayed a selective killing effect on Bcl-
ent protein-protein interactions within the Bcl-2 family,2-positive cancer cells [67]. Most recently, HA14-1 was
since synthetic peptides derived from the BH3 domainshown to induce the apoptosis of primary acute myelog-
of different Bcl-2 family members showed interactionsenous leukemia (AML) and to be synergistic with
with Bcl-xL corresponding to their native proteins [30].PD184352, a MEK inhibitor, in reducing the number of
It remains to be further elucidated as to the amino-acidCFU-blast of primary AML patients 50% more than those
sequence and structural bases that dictate the selectiv-treated with either alone [80]. The potential benefits of
ity and hierarchy of associations between BH3 peptidescombining HA14-1 with other cytotoxic agents in cancer
(or native BH3 domains in proapoptotic proteins) withtreatment were also suggested by another study in
the surface pocket of antiapoptotic Bcl-2 or Bcl-xL. Thewhich the use of HA14-1 together with an epothilone B
experimentally determined structures of proapoptoticanalog was significantly more effective in killing human
Bax and Bid reveal that their BH3 domain is buried inbreast cancer cells than the use of either alone [79]. As
the core of the protein, implying that conformationalto in vivo animal models, although the activity of this
changes are necessary for the BH3 domain to interactand other nonpeptidic inhibitors of Bcl-2 or Bcl-xL have
with its antiapoptotic partners [25–27]. More needs tonot been reported and await further studies, CPM-1285,
be learned about the mechanism and kinetics of thea cell-permeable peptide inhibitor of Bcl-2, has been
conformational switch and refolding of BH3 domainsshown to slow human myeloid leukemia growth in SCID
during their binding to Bcl-2 or Bcl-xL surface pocket.mice [58].
To address these questions, synthetic BH3 peptidesAn important question to be considered in the clinical
may provide a useful model for further investigation em-application of Bcl-2 or Bcl-xL inhibitors is whether these
ploying synthetic and combinatorial chemistry and bio-compounds are toxic to normal cells, which is a common
physical techniques.limitation of current chemotherapeutic drugs. Because
Significant progress in the field was made with thethe function of Bcl-2 is not absolutely necessary in many
recent discovery by several groups independently ofnormal cell types [81], a systemic inhibition of Bcl-2
multiple classes of nonpeptidic inhibitors capable ofmay not affect the normal cellular function. Furthermore,
mimicking the binding of BH3 domain to the surfaceoncogenic changes in certain cancer cells render them
pocket of Bcl-2 and/or Bcl-xL. Whereas the structuresmore susceptible than normal cells to apoptosis [82].
of Bcl-2 or Bcl-xL bound by these inhibitors were pre-This seems to be consistent with the observation that
dicted by using molecular modeling alone or in combina-a higher level of Bcl-2 or Bcl-xL is found in many cancers,
tion with NMR experimental data, high-resolution co-which may serve to protect the vulnerability of these
crystal or NMR structure is needed for the delineationcancers. Therefore, it can be expected that small mole-
of detailed binding modes of these molecules with Bcl-2cule inhibitors targeting cancer cells highly expressing
or Bcl-xL surface pocket. This will be important for theBcl-2 or Bcl-xL are more selective than conventional design of new analogs with higher affinity for the surfacecytotoxic drugs. In this regard, it was encouraging to
pocket. Another important question is the mechanismnote that peptide inhibitor CPM-1285 had little effect on
underlying the specificity of small molecules recognizing
the viability of normal human peripheral blood lympho-
the surface pocket of different Bcl-2 family members.
cytes or the proliferative response of activated lympho-
All of the nonpeptidic inhibitors described above bind
cytes stimulated with PHA mitogen for 48 hr at concen-
both Bcl-2 and Bcl-xL, which may not be surprising giventrations where the peptide strongly induced apoptosis that presumably they all recognize the surface pocket
in cancer cells [58]. Also, a nonpeptidic inhibitor HA14-1 highly conserved in these two proteins. This may be
had no noticeable effect on normal human hematopoi- acceptable or even desirable for clinical application in
etic CD34 cells (determined by the average number of certain cancers, as suggested by the study of antisense
colony-forming cells with or without HA14-1 treatment), oligonucletides that are bispecific for Bcl-2 and Bcl-xL
even though at the same treatment condition HA14-1 [84, 85]. Still, inhibitors with monospecificity for either
strongly decreased the number of CFU-blast of primary Bcl-2 or Bcl-xL are needed if they are to be used to
AML (personal communication, Dr. Michael Andreeff’s probe the function of a specific protein or treat cancer
group at M.D. Anderson Cancer Center). Finally, recent cells where targeting of only one protein is desired.
encouraging data from the clinical trial indicating that Toward the development of such specific inhibitors, the
antisense oligonucleotides targeted against Bcl-2 gene existing compounds can provide starting templates to
can specifically inhibit non-Hodgkin’s lymphoma in hu- generate new derivatives based on structural design
mans provided an important validation of Bcl-2 as a and combinatorial chemistry.
therapeutic target [83]. Since the clinical value of anti- So far, all of the reported small molecule (both peptidic
sense oligonucleotides is often limited by their lack of and nonpeptidic) inhibitors target the surface pocket of
enzymatic stability, cell permeability, and oral activity, antiapoptotic Bcl-2 or Bcl-xL for triggering apoptosis in
small molecule inhibitors devoid of such limitations are cancer cells. It may also be worthwhile to target proapo-
ptotic Bcl-2 family members with small molecules tomore desired agents for clinical application.
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prevent unwanted cell death; for example, to prevent
death of neuronal cells which has been observed in
neurodegerative diseases in which proapoptotic pro-
teins such as Bax and Bad are known to play an impor-
tant role [18]. This is a highly promising and yet currently
unexplored new area of research where the concepts
and methods used for the recent development of small
molecule inhibitors of Bcl-2 and Bcl-xL described above
can be readily applied. Structural biology has revealed
a surprising conservation of both the overall structure
and the surface pocket similar to those of Bcl-2 and
Bcl-xL in Bax, whose surface pocket can also accommo-
date the binding of BH3 domains. Of course, there are
differences in shape and amino-acid composition in the
surface pocket of these Bcl-2 family proteins that pre-
sumably account for differences in affinity and selectiv-
ity in molecular interactions. It is thought that proapo-
ptotic members of the Bcl-2 family possessing a BH3 Figure 6. A Trio that Dictates the Life and Death of Cells
domain “hidden” inside the surface pocket are activated IAPs, such as XIAP, selectively interact with and inhibit caspase-3,
-7, and -9. IAPs also interact with Smac/DIABLO (or its homologsby cleavage by caspases or posttranslational modifica-
Hid, Grim, or Reaper in Drosophila cells), which is released from thetion events to expose the BH3 recognition motif and
mitochrondria together with cytochrome c upon death stimuli. Themanifest death-promoting activity. It is thus intriguing
binding of Smac/DIABLO removes IAPs from their association withto speculate that small molecules bound to the surface
caspases and thus relieves their caspase-inhibiting function. This
pocket of Bax or other proapoptotic proteins might sta- competing binding among the trio of IAPs, caspases, and Smac/
bilize their conformation and prevent the projection of DIABLO leads to either cell survival or death.
the deadly BH3 motif. Therefore, the conformational
changes and molecular recognition involving Bcl-2 fam-
much effort to develop synthetic inhibitors [4, 87]. Here,ily proteins appear to be central for both understanding
I focus on the natural inhibitors of caspases, IAPs.and controlling their biological function.
The IAP family is conserved from viruses to yeast toFinally, understanding the general mechanism by
humans and presently contains eight distinct humanwhich natural as well as designed, synthetic ligands
cellular members that were just discovered in the pastrecognize Bcl-2 family proteins will allow chemistry to
5–6 years, including XIAP (X-linked IAP), c-IAP1, c-IAP2,play a pioneering role in research of apoptosis in the
and survivin [88]. In humans, IAPs such as XIAP, c-IAP1,post-genome era. Currently, the Bcl-2 family already
and c-IAP2 selectively inhibit caspase-3, -7, and -9includes a large number of proteins, many of which
through direct molecular interactions but not caspase-1,await further structure-function characterization. The list
-6, -8, and -10. In addition, IAPs can interact withkeeps expanding as new members are discovered rap-
Smac/DIABLO, which is released from the mitochrondriaidly. Most recently, 24 Bcl-2 homology-containing se-
together with cytochrome c upon death stimuli. Thequences were predicted by using bioinformatic tech-
binding of Smac/DIABLO removes IAPs from their asso-niques from the available human genome databases
ciation with caspases and thus relieves their caspase-[86]. The discoveries of specific ligands for these and
inhibiting function. A similar picture is found in flies:other yet to be identified new members, based on under-
IAPs such as DIAP1 and DIAP2 bind and inhibit severalstanding of molecular recognition and application of
Drosophila caspases, whereas the caspase-inhibitingcomputational and combinatorial chemistry, will provide
action of DIAP1 is removed by the binding of Hid, Grim,a panel of powerful tools for characterizing their func-
or Reaper, which are homologs of Smac/DIABLO in Dro-tions and molecular interactions.
sophila cells [89]. Thus, from flies to mammals, the com-
peting binding among the trio of IAPs, caspases, and
Smac/DIABLO or its functional homologs leads to onlyThe IAPs: A Deadly Trio with Caspases
and Smac/DIABLO one outcome: life or death (Figure 6).
Like the BH domains for the Bcl-2 family, the definingStructure, Function, and Molecular Interactions
Continuing on the topic of protein-protein interactions characteristic of the IAP family is that its members all
share one or more BIR (baculovirus IAP repeat) domainsin apoptosis and their inhibition by small molecules, I
describe another class of molecular interactions involv- (Figure 7A). Among members of the IAP family, XIAP
and survivin have recently received enormous attentioning proteins of the IAP family, which have been the
subjects of intensive biomedical research in recent in the biological and clinical communities [88, 90]. Corre-
spondingly, there has been an explosion in structuralyears, and present new targets for inhibitor design and
discovery. The Bcl-2 and IAP families are regulators of studies of these proteins and their interactions with cas-
pases and Smac/DIABLO which, in just the past threecaspases at two different levels: the Bcl-2 family con-
trols signaling events upstream of capases, while the years, has resulted in the publication (often simultane-
ous publication by two or three independent groups) ofIAP family directly binds and inhibits caspases. Cas-
pases, like other enzymes that are traditionally favored the structures of XIAP [91, 92], survivin [93–95], and the
complex structures of XIAP with caspase-3, -7 [96–98],by the pharmaceutical industry, have been the target of
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found on the BIR2 domain of the DIAP1 protein, a member
of the IAP family which is recognized by the conserved
N-terminal tetrapeptide motif in Hid and Grim [103].
Like Bcl-2 or Bcl-xL, elevated levels of IAPs are found
in cancer cells. XIAP is abnormally overexpressed in
many cancer cells [88]. Survivin is expressed in a variety
of cancers but lacks expression in differentiated adult
tissues [90]. Inhibition of these protein targets by small
molecules may allow for selective elimination of cancer
cells that overexpress IAPs or sensitization of these cells to
chemotherapies. Consistent with this notion, an antisense
oligonucleotide that reduces survivin expression was
shown to induce apoptosis and sensitize lung cancer cells
to a chemotherapeutic drug, etoposide, but had no effect
on the viability of normal blood leukocytes [104].
The Tetrapeptide Binding Pocket on IAPs: Target
for Ligand Design
The surface pocket on XIAP or other IAPs for the binding
of the tetrapeptide motif conserved in both caspase-9
and Smac/DIABLO or its Drosophila homologs Hid,
Grim, and Reaper presents an attractive target for dis-
covering small molecule inhibitors (Figure 7B) [105].
Synthetic peptides or nonpeptidic mimics bound to this
pocket should disrupt the interaction between IAPs and
caspases, thus releasing active caspases-3, -7, and -9
and facilitating apoptosis. In 2000, in vitro studies of
synthetic peptides containing the tetrapeptide motif of
Smac/DIABLO were reported by several groups inde-
pendently. Chai et al. showed that a peptide consisting
of the N-terminal seven residues (i.e., the tetrapeptide
motif plus three additional residues) could promote pro-Figure 7. The BIR Domains of the IAP Family and Their Recognition
caspase-3 activation at 10–300 M, whereas a mutantby Natural and Synthetic Ligands
peptide containing the Met substitution at the Ala-1 po-(A) One or more BIR domains (BIR1-3) shared by the IAP family.
(B) The surface pocket on XIAP bound by the tetrapeptide motif sition or a reversed peptide sequence was not active
[99, 100], which is conserved in both caspase-9 and Smac/DIABLO [106]. Srinivasula et al. synthesized peptides containing
or its Drosophila homologs Hid, Grim, and Reaper. This surface the first 7 or 35 residues of Smac/DIABLO and found that
pocket offers an attractive site for discovering small molecule inhib- both were effective in promoting caspase-3 activation in
itors.
the XIAP-containing extracts at 100–500 M concentra-
tions and that the longer peptide was noticeably more
effective than the short peptide [107].or Smac/DIABLO [99, 100]. From these studies, a picture
of how XIAP works with caspase-3, -7, and Smac/DIA- A detailed analysis of the structure-activity relation-
ship of Smac/DIABLO N-terminal peptides was reportedBLO has emerged [101]. It has been shown that a long
peptide segment preceding the BIR2 domain of XIAP by Liu et al., who determined the NMR structure of the
XIAP BIR3 domain complexed with a nine-residue pep-occupies the active site of caspase-3 or -7 (thus blocking
the access of substrates) and adjacent surfaces that tide derived from Smac/DIABLO and measured the bind-
ing affinity of a series of Smac/DIABLO N-terminal pep-are specific to these two caspases (thus achieving the
specificity over other caspases) [96–98]. However, the tides of various lengths and mutants using a FP
competitive binding assay [100]. This nine-residue pep-mechanism by which XIAP inhibits caspase-9 is quite
different. Rather than directly restricting the enzyme ac- tide adopts an extended conformation with a kink at
Pro3 when bound to the surface pocket on XIAP BIR3tive site for substrate cleavage, the BIR3 domain of
XIAP interacts with the N-terminal tetrapeptide (ATPF) domain (Figure 7B). The main chain of Ala-1, Val-2, and
Ile-4 forms extensive hydrogen bonds with the pocket,of caspase-9, which becomes available after the cleav-
age of procaspase-9, thus sequestering caspase-9 and while the side chains of Val-2, Pro3, and Ile-4 engage in
hydrophobic interactions. By contrast, residues beyondpreventing it from its deadly action [102]. Surprisingly,
a similar tetrapeptide motif (AVPI) exists in the N termi- this tetrapeptide motif do not show any interaction with
the pocket. On the pocket, mutational analysis has sug-nus of Smac/DIABLO that has been shown in X-ray and
NMR structures to bind to a surface pocket on the BIR3 gested the important role in ligand binding of residues
Leu-307, Trp-310, Trp-323, E314, and D296. Consistentdomain of XIAP [99, 100]. Thus, Smac/DIABLO competes
with the same tetrapeptide binding pocket on the XIAP with the NMR and mutational analyses, synthetic pep-
tides containing modifications at the N-terminal amineBIR3 domain and relieves XIAP from its complex with
caspase-9. In Drosophila, a similar binding pocket is (Ala-1) or Ala replacement at Val-2, Pro3, or Ile-4 resulted
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in loss or decrease in XIAP binding. Interestingly, a pep- The rapid progress made recently in the discovery of
nonpeptidic inhibitors of Bcl-2 and Bcl-xL seems to sug-tide containing only the first five residues is almost as
potent as the nine-residue peptide. gest that similar advances in the study of IAPs may not
be far off, given the enormous interest in these proteinsMore recently, combinatorial chemistry has been ap-
plied to the development of novel ligands for the tetra- in both academia and pharmaceutical companies.
peptide binding pocket on the BIR3 domain of IAPs.
Kipp et al. synthesized libraries of tetrapeptides using
Conclusion
the Smac/DIABLO N-terminal sequence as a starting
A highly regulated network of protein-protein interac-
point [108]. With a competitive binding assay based on
tions is the central theme underlying the machinery of
a solvent-sensitive fluorogenic dye molecule, badan, the
programmed cell death. Understanding the chemical
binding affinities of these tetrapeptides, which contain
basis of these interactions is a key to unlock the mystery
variations at different residues, were determined in order
of life and death of cells at the atomic level, while control-
to dissect the contribution of each residue of the tetra-
ling the outcome of these interactions offers tremendous
peptide to the total binding energy with the surface
benefits in the treatment of many human diseases. Fo-
pocket on the BIR3 domain of XIAP. From the analysis
cusing on the Bcl-2 family as a model system, I summa-
of a total of six libraries of related tetrapeptides, it was
rize the progress, especially during the last two years,
found that Arg and Phe substitutions at positions 2 and
in the discovery of small molecule ligands targeting
4, respectively, led to significant increase in binding
Bcl-2 or Bcl-xL and use of these ligands as both probesaffinity. Combining these two substitutions resulted in
and inhibitors of relevant molecular interactions and bio-
a tetrapeptide, ARPF, that had the highest affinity, with
logical function. These studies have provided an exciting
a KD of 20 nM. prospect in further developing and using these novel
small molecules for chemical biological research of mo-
lecular interactions involving the Bcl-2 family and inFuture Research in Molecule Recognition
applying similar strategies to explore and control otherand Drug Design of the IAP Family
molecular interactions that are also important for apo-The interactions of the IAP family with caspases and
ptosis. The interactions of IAPs with caspases andSmac/DIABLO present new targets for inhibitor design.
Smac/DIABLO is one additional example described inAs highlighted by the tetrapeptide binding pocket on
this article for the application of small molecule ap-the IAPs, small synthetic peptides derived from Smac/
proaches to study intracellular protein-protein interac-DIABLO have been shown to be active in inhibiting the
tions mediating apoptotic signaling. Besides Bcl-2 andfunction of IAPs and promoting caspase activation. De-
IAP families, there are many other protein-protein inter-spite their small sizes (the shortest being four residues),
actions that can be targeted by structure-based andthese peptides display high affinity for the IAP BIR3
chemical biological strategies, such as those involvingdomain, down to the low nM concentrations. These re-
FADD adaptor motifs, various procaspases, Apaf-1, andsults strongly suggest the feasibility of discovering small
apoptosome, just to name a few. With the frenetic pacemolecules capable of mimicking the effect of Smac/
of biomedical research in apoptosis, the list of knownDIABLO. While some of these Smac/DIABLO peptides
and yet to be known protein-protein interactions of bothwere shown to cause the activation of caspase-3 in vitro,
biological and therapeutic significance goes on and sofurther studies are needed to demonstrate whether they
does the tremendous challenge and opportunity forcan promote caspase activation and apoptosis in living
chemists and biochemists in years to come.cells and animals. Interestingly, short peptides con-
taining the N-terminal four or seven residues of Smac/
AcknowledgmentsDIABLO were able to enter Jurkat cells and potentiate
apoptosis triggered by other agents [109]. To improve
I apologize to my colleagues if I have missed or failed to cite theirthe cell permeability of IAP targeting peptides, the strat-
works and papers here due to the specific focus and space con-
egies described above in the studies of cell-permeable straint of this review and the rapid development of this field. The
peptide inhibitors of Bcl-2 may be readily applied. In- work conducted in our laboratory was supported by grants from
the National Institutes of Health, the American Cancer Society, anddeed, a recent paper by Fulda et al. showed that a Smac
the Sidney Kimmel Foundation for Cancer Research. I would likeN-terminal seven-residue peptide linked to the protein
to thank Professors Robert Gennis, Paul Hergenrother, and Johntransduction domain of HIV Tat protein sensitized tumor
Katzenellenbogen (University of Illinois at Urbana-Champaign) forcells to the effect of apoptosis-inducing agents in vitro
helpful comments and suggestions and Dr. Dongxiang Liu for help
and in vivo [110]. in preparing the figures.
Perhaps a more important goal will be the transforma-
tion of the high-affinity tetrapeptide into nonpeptidic
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